PR
Public Relations
Home
PR
Media release
"TRX-221" from Therapex Grabs the Attention of Global Cancer Experts
NOTICE
2023-04-19

 

Preclinical results announced for the fourth-generation lung cancer drug candidate “TRX-221"

 

 

 

Therapex, a Korean cancer drug development company, recently drew attention from cancer specialists worldwide at one of the prominent international oncology conferences, the American Association for Cancer Research (AACR) Annual Meeting 2023, by unveiling the first glimpse of their fourth-generation lung cancer drug candidate, "TRX-221".

 

On April 18th, Therapex presented the preclinical results of TRX-221, a fourth-generation EGFR inhibitor candidate, in the poster presentation session at the AACR 2023 held in Florida, USA.

 

​Therapex CEO Koo Lee PhD presenting the preclinical results of their fourth-generation EGFR inhibitor candidate, 'TRX-221', at the AACR 2023 in Florida, USA, on the 18th of April.

 

 

 

Held annually in April, the AACR Meetings are one of the largest international academic events in the field of oncology, where researchers and biotech and pharmaceutical industry experts from all around the world gather to share innovative cancer treatment technologies and R&D achievements.

 

TRX-221, unveiled by Therapex, is a fourth-generation broad-spectrum EGFR inhibitor drug candidate (Broad-Spectrum Fourth-Generation EGFR TKI) designed to target a range of mutations. It not only targets the resistance mutation C797S that appears after treatment with third-generation EGFR inhibitors widely used for non-small cell lung cancer treatment, such as "Tagrisso" (ingredient name: Osimertinib), but also inhibits mutations targeted by first to third-generation EGFR inhibitors (ex19del, L858R, T790M).

 

Therapex's poster presentation received keen interest from numerous researchers, professors, and biotech and pharmaceutical industry experts in the field of lung cancer drug development, leading to in-depth question-and-answer sessions and scientific discussions.

Experts were particularly intrigued by the data confirming dose-dependent anti-cancer efficacy in mouse models known as Patient-Derived Organoid Xenografts (PDOX), which are recognized for their physiological relevance to the tumor biology of actual lung cancer patients. These models were transplanted with tumors derived from lung cancer patients resistant to Tagrisso, a first in its presentation to the world.

 

TRX-221 garnered attention for significantly prolonging survival mouse models with Tagrisso-resistant brain tumors compared to the control group. Its ability to permeate the blood-brain barrier (BBB) was another point of interest, indicating its potential intracranial effects on brain tumors.

 

Therapex CEO Koo Lee PhD, who directly presented this data, stated, "By sharing the preclinical results of TRX-221 and engaging in active discussion with experts in the field of lung cancer drug development, we could feel the global interest in the fourth-generation EGFR TKI lung cancer drugs.” He further added, “We plan to highlight the superiority of TRX-221 through various domestic and international conferences in the future, while also expediting its development and commercialization.”

 

Meanwhile, Therapex is gearing up to submit an Investigational New Drug (IND) application for Phase 1 studies to both the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) and the U.S. Food and Drug Administration (FDA) in June. The company aims to commence clinical trials on human subjects in the latter half of the year.

 

 

Source: "Cheongnyeon Doctor News", Reporter Kim Yoon-mi (http://www.docdocdoc.co.kr/news/articleView.html?idxno=3005025)

List